Navigation Links
Amarantus Announces Upcoming Investor Presentations
Date:5/27/2016

SAN FRANCISCO, May 27, 2016 /PRNewswire/ --

Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that President & CEO Gerald E. Commissiong will be presenting at two upcoming investor conferences:

SeeThru Equity MicroCap Conference 

Where: Convene Conference Center, 730 Third Avenue, New York City, NY

When: Tuesday, May 31st, 2016 at 3:00pm

Marcum MicroCap Conference 

Where: Grand Hyatt Hotel, 109 East 42nd St, New York, NY

When: Wednesday, June 1st, 2016 at 3:00pm

About Amarantus BioScience Holdings, Inc. 

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture. ESS is entering Phase 2 clinical studies under a CRADA agreement with the US Army. AMBS has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression, and owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) and is developing MANF-based products as treatments for brain and ophthalmic disorders. AMBS also owns 80 million shares of Avant Diagnostics, Inc. via the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc. MANF was discovered from the Company's proprietary discovery engine PhenoGuard.

For further information please visit http://www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

Forward-Looking Statements 

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

Investor and Media Contact:
Ascendant Partners, LLC
Fred Sommer
+1-732-410-9810
fred@ascendantpartnersllc.com



'/>"/>
SOURCE Amarantus BioScience Holdings, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Amarantus Announces Cancellation of Special Meeting of Shareholders
2. Amarantus Appoints Brian E. Harvey, MD PhD to Strategic Advisory Board
3. Amarantus to Present at Source Capital Groups 2016 Disruptive Growth & Healthcare Conference
4. Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)
5. Amarantus Enters Into Letter of Intent to Merge Diagnostics Business Unit Into Avant Diagnostics
6. Amarantus to Present at ICV Sonoma Event
7. Amarantus to Present at SeeThruEquity First Annual Microcap Healthcare Investor Conference
8. Amarantus Requests Rare Pediatric Disease and Orphan Drug Designations from US FDA for Engineered Skin Substitute in the Treatment of Giant Congenital Melanocytic Nevi
9. Amarantus Provides Update on cGMP Manufacturing Validation for the Engineered Skin Substitute (ESS) Program
10. Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Method of Treating Parkinsons Disease Levodopa-induced Dyskinesia (PD-LID)
11. NxStage Announces Second Quarter 2016 Investor Conference Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/14/2020)... ... , ... A new study from the National Alliance for Caregiving (NAC) and ... 9.5 million from 2015 to 2020 and now encompasses more than one in five ... worse health compared to five years ago. As the demand for caregiving rises with ...
(Date:5/14/2020)... ... 2020 , ... Clear Labs , providers of the only automated and ... funding led by Redmile Group, as well as existing investors including Wing VC, Menlo ... Labs has raised $62M. , In addition to supporting ongoing commercialization of the ...
(Date:5/14/2020)... ... May 13, 2020 , ... The DuPont Kingston Technology ... spread of COVID-19 in the local community. To date, more than 4,000 liters of ... and small businesses. An additional 2500 liters of hand sanitizer will be produced and ...
Breaking Medicine Technology:
(Date:5/21/2020)... ... May 21, 2020 , ... A new report from ... over 90 companies involved in the point of care test industry. Given the ... testing, COVID-19 has made point-of-care more important than in the past, according to the ...
(Date:5/16/2020)... ... May 15, 2020 , ... ... new collaboration with the Open Source Medical Supplies (OSMS). The organization will obtain ... efforts to reduce the spread of COVID-19. , Created as a response to ...
(Date:5/15/2020)... NEW YORK (PRWEB) , ... May 15, 2020 , ... ... will come together for Home is Where the Heart Is, a benefit to support ... a rare genetic disorder that causes tumors to grow on nerves throughout the body ...
(Date:5/14/2020)... (PRWEB) , ... May 14, 2020 , ... SGF , a premier fertility and ... of fertility procedures and treatment in the Tampa Bay region. , “While this pandemic has ... ways our team members and patients have risen to the occasion. Through the work of ...
(Date:5/14/2020)... STEVENSVILLE, Md. (PRWEB) , ... May 13, 2020 , ... ... with the Centers for Medicare and Medicaid Services (CMS), DLA awarded Federal Resources a ... million gowns, and 64.4 million pairs of gloves to ensure the safety and well-being ...
Breaking Medicine News(10 mins):